BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 174 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q1 2019. The put-call ratio across all filers is 0.44 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $18,344,000 | -14.0% | 154,706 | 0.0% | 0.26% | -10.2% |
| Q4 2021 | $21,321,000 | -0.8% | 154,706 | 0.0% | 0.29% | +2.1% |
| Q3 2021 | $21,491,000 | +43.1% | 154,706 | 0.0% | 0.29% | +30.9% |
| Q2 2021 | $15,018,000 | +42.0% | 154,706 | 0.0% | 0.22% | +50.7% |
| Q1 2021 | $10,574,000 | -20.3% | 154,706 | 0.0% | 0.15% | -23.2% |
| Q4 2020 | $13,261,000 | -48.1% | 154,706 | -60.6% | 0.19% | -58.7% |
| Q3 2020 | $25,546,000 | -34.9% | 392,956 | -26.8% | 0.46% | -36.6% |
| Q2 2020 | $39,225,000 | +4.5% | 536,530 | -26.4% | 0.72% | -18.3% |
| Q1 2019 | $37,531,000 | +10.1% | 729,178 | -20.9% | 0.89% | +9.5% |
| Q4 2018 | $34,078,000 | +30.8% | 921,536 | +32.8% | 0.81% | +37.3% |
| Q3 2018 | $26,063,000 | +70.5% | 694,104 | +79.5% | 0.59% | +65.3% |
| Q2 2018 | $15,283,000 | +47.8% | 386,724 | -3.6% | 0.36% | +57.3% |
| Q1 2018 | $10,339,000 | – | 401,322 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 1,111,111 | $154,344,000 | 72.03% |
| Knoll Capital Management, LLC | 856,844 | $119,024,000 | 59.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,124,055 | $295,053,000 | 36.73% |
| ARS Investment Partners, LLC | 466,668 | $64,825,000 | 6.49% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 365,373 | $50,754,000 | 6.18% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $24,490,000 | 5.91% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 61,897 | $8,598,000 | 4.86% |
| DAFNA Capital Management LLC | 88,100 | $12,238,000 | 3.25% |
| Avidity Partners Management LP | 934,200 | $129,770,000 | 2.88% |
| Eventide Asset Management | 1,325,000 | $184,056,000 | 2.43% |